These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17435339)

  • 1. [Candidate drugs for non-alcoholic steatohepatitis (NASH)].
    Terai S; Matsumoto T; Sakaida I
    Nihon Yakurigaku Zasshi; 2007 Apr; 129(4):271-5. PubMed ID: 17435339
    [No Abstract]   [Full Text] [Related]  

  • 2. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy.
    Tsochatzis EA; Papatheodoridis GV; Archimandritis AJ
    Mediators Inflamm; 2009; 2009():831670. PubMed ID: 19753129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug therapy for non-alcoholic steatohepatitis].
    Tomita K; Hibi T
    Nihon Rinsho; 2006 Jun; 64(6):1146-51. PubMed ID: 16768123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adipokine interrelationship with the liver].
    Takei Y; Sato N
    Nihon Rinsho; 2006 Jun; 64(6):1083-7. PubMed ID: 16768113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiponectin, structure, function and pathophysiological implications in non-alcoholic fatty liver disease.
    Méndez-Sánchez N; Chavez-Tapia NC; Zamora-Valdés D; Uribe M
    Mini Rev Med Chem; 2006 Jun; 6(6):651-6. PubMed ID: 16787375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of fatty liver disease].
    Cobo Martín M; Fernández Gil P; Crespo J
    Gastroenterol Hepatol; 2008 Apr; 31(4):229-38. PubMed ID: 18405489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Syndrome X].
    Kotake H
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():706-11. PubMed ID: 12430306
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical utility of angiotensin II receptor antagonist].
    Yokohama S; Nakamura K; Haneda M
    Nihon Rinsho; 2006 Jun; 64(6):1152-6. PubMed ID: 16768124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diabetes and the metabolic syndrome].
    Yamauchi T; Kadowaki T
    Nihon Yakurigaku Zasshi; 2006 Sep; 128(3):133-40. PubMed ID: 16971775
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging drugs for non-alcoholic steatohepatitis.
    Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
    Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
    Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
    Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
    Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiology of NASH].
    Takei Y; Ikejima K; Sato N
    Nihon Shokakibyo Gakkai Zasshi; 2004 Nov; 101(11):1194-203. PubMed ID: 15570867
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacologic therapy of non-alcoholic steatohepatitis.
    Ratziu V; Zelber-Sagi S
    Clin Liver Dis; 2009 Nov; 13(4):667-88. PubMed ID: 19818312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?
    Bugianesi E; Zannoni C; Vanni E; Marzocchi R; Marchesini G
    Dig Liver Dis; 2004 Mar; 36(3):165-73. PubMed ID: 15046183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?
    Hui JM; Hodge A; Farrell GC; Kench JG; Kriketos A; George J
    Hepatology; 2004 Jul; 40(1):46-54. PubMed ID: 15239085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mutltifaceted biological roles of adiponectin].
    Cuerq C; Morineau G; Dufour-Rainfray D; Vatier C; Fellahi S; Vigouroux C; Genoux A; Lacorte JM; Charchour R; Fève B; Capeau J; Collet C; Bastard JP;
    Ann Biol Clin (Paris); 2020 Jun; 78(3):243-252. PubMed ID: 32540813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.